Healthcare Industry News: SynapDx
News Release - June 1, 2010
SynapDx Corporation Raises $9 Million in Series A Funding
Company to Develop Proprietary Technologies for the Early Detection of Autismprnewswire
WALTHAM, Mass., June 1 -- (Healthcare Sales & Marketing Network) -- SynapDx Corp., a new company focused on developing and commercializing diagnostic testing for the early detection of autism, announced the completion of a $9 million Series A financing by Bain Capital Ventures, General Catalyst Partners, and North Bridge Venture Partners.
"Autism has a profound effect on children and their families," said Stanley N. Lapidus, the company's founder, President and Chief Executive Officer. "The right objective blood-based diagnostic test for autism may help achieve earlier diagnosis, more rapid intervention, and improved outcomes."
About SynapDx Corp.
SynapDx was formed to develop and commercialize blood-based diagnostic tests for the early detection of autism. SynapDx was founded by Stanley N. Lapidus, an experienced life-sciences entrepreneur and inventor with 31 issued patents. Mr. Lapidus founded and led Cytyc Corp., EXACT Sciences Corp., and Helicos BioSciences Corp. Mr. Lapidus' co-founders of SynapDx Corp. include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.
www.SynapDx.com
Source: SynapDx
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
